• Jason J LeBlanc, May ElSherif, Lingyun Ye, Donna MacKinnon-Cameron, Li Li, Ardith Ambrose, Todd F Hatchette, Amanda L Lang, Hayley Gillis, Irene Martin, Melissa K Andrew, Guy Boivin, William Bowie, Karen Green, Jennie Johnstone, Mark Loeb, Anne McCarthy, Allison McGeer, Sanela Moraca, Makeda Semret, Grant Stiver, Sylvie Trottier, Louis Valiquette, Duncan Webster, Shelly A McNeil, and Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).
• Canadian Center for Vaccinology (CCfV), IWK Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, Nova Scotia (NS), Canada. Electronic address: jason.leblanc@nshealth.ca.
• Vaccine. 2017 Jun 22; 35 (29): 3647-3654.

BackgroundPneumococcal community acquired pneumonia (CAPSpn) and invasive pneumococcal disease (IPD) cause significant morbidity and mortality worldwide. Although childhood immunization programs have reduced the overall burden of pneumococcal disease, there is insufficient data in Canada to inform immunization policy in immunocompetent adults. This study aimed to describe clinical outcomes of pneumococcal disease in hospitalized Canadian adults, and determine the proportion of cases caused by vaccine-preventable serotypes.MethodsActive surveillance for CAPSpn and IPD in hospitalized adults was performed in hospitals across five Canadian provinces from December 2010 to 2013. CAPSpn were identified using sputum culture, blood culture, a commercial pan-pneumococcal urine antigen detection (UAD), or a serotype-specific UAD. The serotype distribution was characterized using Quellung reaction, and PCR-based serotyping on cultured isolates, or using a 13-valent pneumococcal conjugate vaccine (PCV13) serotype-specific UAD assay.Results And ConclusionsIn total, 4769 all-cause CAP cases and 81 cases of IPD (non-CAP) were identified. Of the 4769 all-cause CAP cases, a laboratory test for S. pneumoniae was performed in 3851, identifying 14.3% as CAPSpn. Of CAP cases among whom all four diagnostic test were performed, S. pneumoniae was identified in 23.2% (144/621). CAPSpn cases increased with age and the disease burden of illness was evident in terms of requirement for mechanical ventilation, intensive care unit admission, and 30-day mortality. Of serotypeable CAPSpn or IPD results, predominance for serotypes 3, 7F, 19A, and 22F was observed. The proportion of hospitalized CAP cases caused by a PCV13-type S. pneumoniae ranged between 7.0% and 14.8% among cases with at least one test for S. pneumoniae performed or in whom all four diagnostic tests were performed, respectively. Overall, vaccine-preventable pneumococcal CAP and IPD were shown to be significant causes of morbidity and mortality in hospitalized Canadian adults in the three years following infant PCV13 immunization programs in Canada.Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

28 keywords...

hide…